Oral neomycin and erythromycin compared with single-dose systemic metronidazole and ceftriaxone prophylaxis in elective colorectal surgery.
A prospective randomized trial was performed to compare oral neomycin and erythromycin with single-dose intravenous metronidazole and ceftriaxone in elective colorectal surgery. The study was discontinued after 60 patients were entered. The overall rate of infection was 41 percent in the oral neomycin and erythromycin group (n = 29) compared with 9.6 percent in those who received intravenous metronidazole and ceftriaxone (n = 31) (p less than 0.01). Infections in the oral group were principally due to resistant Staphylococcus aureus, Bacteroides fragilis, and Escherichia coli. Preoperative administration of oral neomycin and erythromycin was associated with a significant reduction of Escherichia coli counts (1 X 10(7) to 3 X 10(5) organisms/ml, p less than 0.05) compared with the intravenous group, but there was no significant reduction in the counts of Bacteroides fragilis (2 X 10(8) to 1 X 10(7) organisms/ml) and there was an increase in the counts of Clostridia (2 X 10(4) to 1 X 10(6) organisms/ml). These results indicate that single-dose systemic prophylaxis with appropriate antibiotics is superior to oral neomycin and erythromycin.
Weaver
M
M
Burdon
D W
DW
Youngs
D J
DJ
Keighley
M R
MR
D000284:Administration, Oral; D001441:Bacteroides fragilis / Q000302:isolation & purification; D002443:Ceftriaxone / Q000008:administration & dosage* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003013:Clostridium / Q000302:isolation & purification; D003106:Colon / Q000382:microbiology / Q000601:surgery*; D004359:Drug Therapy, Combination; D004917:Erythromycin / Q000008:administration & dosage* / Q000627:therapeutic use; D004926:Escherichia coli / Q000302:isolation & purification; D006801:Humans; D017053:Infection Control; D007239:Infections / Q000382:microbiology; D007275:Injections, Intravenous; D008795:Metronidazole / Q000008:administration & dosage* / Q000627:therapeutic use; D009355:Neomycin / Q000008:administration & dosage* / Q000627:therapeutic use; D011183:Postoperative Complications / Q000517:prevention & control; D011292:Premedication; D011897:Random Allocation; D012007:Rectum / Q000382:microbiology / Q000601:surgery*; D013211:Staphylococcus aureus / Q000302:isolation & purification; D014946:Wound Infection / Q000382:microbiology
D008795:Metronidazole; D004917:Erythromycin; D002443:Ceftriaxone; D009355:Neomycin